Compare AZZ & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZZ | ADPT |
|---|---|---|
| Founded | 1956 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | N/A | 2019 |
| Metric | AZZ | ADPT |
|---|---|---|
| Price | $125.34 | $18.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $116.33 | $16.70 |
| AVG Volume (30 Days) | 152.8K | ★ 2.0M |
| Earning Date | 01-07-2026 | 02-05-2026 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | ★ 730.47 | N/A |
| EPS | ★ 10.65 | N/A |
| Revenue | ★ $1,616,858,000.00 | $252,754,000.00 |
| Revenue This Year | $5.09 | $50.86 |
| Revenue Next Year | $5.31 | $0.53 |
| P/E Ratio | $11.57 | ★ N/A |
| Revenue Growth | 1.53 | ★ 42.57 |
| 52 Week Low | $70.90 | $6.26 |
| 52 Week High | $127.88 | $20.76 |
| Indicator | AZZ | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 67.86 | 54.89 |
| Support Level | $121.26 | $16.55 |
| Resistance Level | $127.88 | $19.42 |
| Average True Range (ATR) | 2.68 | 0.94 |
| MACD | -0.10 | 0.09 |
| Stochastic Oscillator | 75.27 | 69.48 |
AZZ Inc is a provider of galvanizing and a variety of metal coating solutions and coil coating solutions to a broad range of end markets in North America. The company's operating segment consists of Metal Coatings, Precoat Metals, and Infrastructure Solutions. The company generates the majority of its revenue from the Precoat Metals segment, which provides coil coating application of protective and decorative coatings and related value-added downstream processing for steel and aluminum coils. Geographically, the company generates the majority of its revenue from the United States.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).